Vanguard Group Inc Angion Biomedica Corp. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.8 - $1.0 $540 - $675	675 Added 0.1%	644,035 $521,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $1.23 $119,693 - $156,620	-127,334 Reduced 16.52%	643,360 $592,000
Q2 2022 Aug 12, 2022	BUY	$1.1 - $2.23 $149,436 - $302,947	135,851 Added 21.4%	770,694 $878,000
Q1 2022 May 13, 2022	SELL	$1.72 - $2.96 $461,458 - $794,138	-268,290 Reduced 29.71%	634,843 $1.35 Million
Q4 2021 Feb 14, 2022	BUY	$2.35 - $9.95 $4,906 - $20,775	2,088 Added 0.23%	903,133 $2.62 Million
Q3 2021 Nov 12, 2021	BUY	$9.31 - $13.25 $6.04 Million - $8.6 Million	648,753 Added 257.14%	901,045 $8.8 Million
Q2 2021 Aug 13, 2021	BUY	$13.02 - $17.83 $3.28 Million - $4.5 Million	252,292 New	252,292 $3.29 Million

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.